Shopping Cart
- Remove All
Your shopping cart is currently empty
KIRA-7
KIRA-7 is an imidazopyrazine compound. KIRA-7 has an anti-fibrotic effect. KIRA-7 binds the IRE1α kinase (IC50: 110 nM) to allosterically inhibit its RNase activity.
Catalog No. T15664Cas No. 1937235-76-1
Resource Download
KIRA-7
Catalog No. T15664Cas No. 1937235-76-1
KIRA-7 is an imidazopyrazine compound. KIRA-7 has an anti-fibrotic effect. KIRA-7 binds the IRE1α kinase (IC50: 110 nM) to allosterically inhibit its RNase activity.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,370 | 6-8 weeks | |
| 50 mg | $1,780 | 6-8 weeks | |
| 100 mg | $2,800 | 6-8 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreProduct Introduction
Bioactivity
Chemical Properties
| Description | KIRA-7 is an imidazopyrazine compound. KIRA-7 has an anti-fibrotic effect. KIRA-7 binds the IRE1α kinase (IC50: 110 nM) to allosterically inhibit its RNase activity. |
| Targets&IC50 | IRE1α kinase:110 nM |
| In vitro | In the alveolar epithelial cell line MLE12, KIRA-7 inhibits XBP1 splicing [1]. |
| In vivo | After Bleomycin exposure, mRNA levels of BiP and CHOP are significantly elevated, and treatment of Bleomycin-exposed mice with KIRA-7 decreased these levels. KIRA-7 (5 mg/kg; intraperitoneal injection; daily for 14 days; C57BL6 mice) treatment causes decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice treated with vehicle. mRNA levels of collagen 1A1 and fibronectin are both significantly decreased by KIRA-7 treatment [1]. |
| Molecular Weight | 466.51 |
| Formula | C27H23FN6O |
| Cas No. | 1937235-76-1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy KIRA-7 | purchase KIRA-7 | KIRA-7 cost | order KIRA-7 | KIRA-7 chemical structure | KIRA-7 in vivo | KIRA-7 in vitro | KIRA-7 formula | KIRA-7 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.